Evaluation of Efficacy of Denosumab in Adult Patients With Langerhans Cell Histiocytosis (LCH): a Multiple-site, Single Arm, Open Label Clinical Trial
Phase of Trial: Phase II
Latest Information Update: 17 Oct 2019
Price : $35 *
At a glance
- Drugs Denosumab (Primary)
- Indications Langerhans cell histiocytosis
- Focus Therapeutic Use
- 21 Feb 2019 Planned End Date changed from 30 Jun 2020 to 30 Jun 2021.
- 21 Feb 2019 Planned primary completion date changed from 28 Feb 2020 to 28 Feb 2021.
- 09 Jun 2017 New trial record